| Morgan Felix, MS CCC-SLP | |
|
401 Washington Blvd Apt 3507, Jersey City, NJ 07310-2232 | |
| (908) 670-0288 | |
| Not Available |
| Full Name | Morgan Felix |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 401 Washington Blvd Apt 3507, Jersey City, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144766932 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 41YS00866500 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Morgan Felix, MS CCC-SLP 401 Washington Blvd Apt 3507, Jersey City, NJ 07310-2232 Ph: (908) 670-0288 | Morgan Felix, MS CCC-SLP 401 Washington Blvd Apt 3507, Jersey City, NJ 07310-2232 Ph: (908) 670-0288 |
News Archive
In FDLI's latest monograph, Selling Pharmaceuticals and Biologics to the Federal Government: Federal Supply Schedule and Federal Pricing Requirements, Joy Sturm, Allison Pugsley and Stephen A. Smyers of Hogan Lovells US LLP detail how pharmaceutical and biologics manufacturers can deal effectively with government contracting requirements and price calculation requirements.
Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to GlaxoSmithKline's Lamictal® ODT.
The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.
› Verified 5 days ago
Speech Quest Jcny Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 581 Jersey Ave, Jersey City, NJ 07302 Phone: 201-381-1607 Fax: 201-216-9171 | |
Mr. Josephus Reynes, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 54 Towers St, Jersey City, NJ 07305 Phone: 917-226-1181 | |
Alisha Beth Cipollone, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 299 Pavonia Avenue, 1-3, Jersey City, NJ 07302 Phone: 917-478-3042 | |
Maria Pasahol, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 Journal Square Plz, Jersey City, NJ 07306 Phone: 551-247-1306 | |
Katie Michele Hanily, M.A. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 Journal Square Plz Ste 610, Jersey City, NJ 07306 Phone: 551-247-1306 | |
Sensorykids,llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 278 Monmouth St, Jersey City, NJ 07302 Phone: 201-324-1700 | |
Elizabeth Bornstein, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 263 Whiton St Apt 2, Jersey City, NJ 07304 Phone: 908-625-2550 Fax: 908-232-3583 |